HighTower Advisors LLC purchased a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 781,752 shares of the company's stock, valued at approximately $12,039,000. HighTower Advisors LLC owned 5.40% of Inhibrx at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Inhibrx during the fourth quarter valued at about $348,000. Exchange Traded Concepts LLC bought a new stake in Inhibrx during the fourth quarter valued at about $148,000. China Universal Asset Management Co. Ltd. bought a new stake in Inhibrx during the fourth quarter valued at about $47,000. Rhumbline Advisers bought a new stake in Inhibrx during the fourth quarter valued at about $228,000. Finally, New York State Common Retirement Fund bought a new stake in Inhibrx during the fourth quarter valued at about $53,000. 82.46% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a report on Wednesday, January 22nd.
Get Our Latest Analysis on INBX
Inhibrx Stock Up 0.8 %
Shares of INBX traded up $0.12 during trading hours on Thursday, reaching $14.12. 33,381 shares of the company traded hands, compared to its average volume of 217,169. The stock's fifty day moving average is $13.28 and its 200 day moving average is $14.66. Inhibrx, Inc. has a 1-year low of $10.80 and a 1-year high of $35.42.
Inhibrx (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings data on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing analysts' consensus estimates of ($2.88) by ($0.21). The firm had revenue of $0.10 million for the quarter. On average, equities research analysts expect that Inhibrx, Inc. will post 104.88 earnings per share for the current year.
Inhibrx Company Profile
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Further Reading
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
